Exocrine Pancreatic Insufficiency Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight's, "Exocrine Pancreatic Insufficiency Pipeline Insight 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Exocrine Pancreatic Insufficiency pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Exocrine Pancreatic Insufficiency Pipeline Report
• DelveInsight's Exocrine Pancreatic Insufficiency Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Exocrine Pancreatic Insufficiency.
• The leading Exocrine Pancreatic Insufficiency Companies working in the market include Digestive Care, Inc., AzurRx BioPharma, Inc., Abbott, Orlando Health, Inc., Chiesi Farmaceutici, and others.
• Promising Exocrine Pancreatic Insufficiency Therapies in the various stages of development include SA-001, EUR-1008 (APT-1008), adrulipase, and others.
• April 2024:- First Wave Biopharma Inc.- A Phase 2, Open Label, Multicenter, Pilot Study to Assess Safety and Efficacy of an Enteric Microgranule Formulation of Adrulipase in Patients With Exocrine Pancreatic Insufficiency (EPI) Due to Cystic Fibrosis (CF). This is an Phase 2, open label, single arm pilot study assessing the safety and efficacy of adrulipase in an enteric microgranule formulation. Patients with a confirmed diagnosis of cystic fibrosis who are 18 years of age or greater will be screened for eligibility if they have been clinically controlled on a stable dose of commercial pancreatic enzyme replacement therapy (PERT) for at least one month.
• April 2024-- Children's Hospital of Philadelphia- This is a clinical trial with a cross over design investigating the effect of the proton pump inhibitor omeprazole on fat malabsorption in subjects with cystic fibrosis and pancreatic insufficiency. Participants will be randomized to receive either omeprazole or placebo for 28 days, then cross over and receive omeprazole or placebo for another 28 days. Markers of fat absorption will be measured after each treatment course.
• April 2024:- Centre Hospitalier Universitaire de Liege- Every year, thousands of children around the world are born with rare genetic diseases leading to death or lifelong disability. With technological advancements in the field of genetics and medicine, the rate of introduction of treatments for these rare conditions has grown remarkably.

To explore more information on the latest breakthroughs in the Exocrine Pancreatic Insufficiency treatment landscape of the report, click here @ Exocrine Pancreatic Insufficiency Pipeline Outlook- https://www.delveinsight.com/sample-request/exocrine-pancreatic-insufficiency-epi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Exocrine Pancreatic Insufficiency Overview
Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or maldigestion. The exocrine pancreas produces three main types of enzymes: amylase, protease, and lipase. Under normal physiologic conditions, the enzymes (specifically, lipase) break undigested triglycerides into fatty acids and monoglycerides, which are then solubilized by bile salts (see Pathophysiology).

Exocrine Pancreatic Insufficiency Emerging Drugs Profile

• MS1819: AzurRx BioPharma/Mayoly-Spindler
MS1819, a recombinant lipase derived from the yeast Yarrowia Lipolytica, is in development for the treatment of exocrine pancreatic insufficiency (EPI) associated with chronic pancreatitis (CP) and cystic fibrosis (CF). Early Phase Ib data in EPI patients treated with MS1819 showed a favorable safety profile and encouraging preliminary signals of efficacy. AzurRx is currently conducting a Phase IIa trial of MS1819 for the treatment of exocrine pancreatic insufficiency (EPI) associated with chronic pancreatic pancreatitis (CP). The study is being performed at four sites in Australia and New Zealand with a target enrollment of 12-15 patients. In addition to assessing safety, AzurRx is evaluating four escalating dose increments of MS1819, with the aim of elucidating the optimal treatment dose to be taken into subsequent registration trials in EPI patients with chronic pancreatitis (CP) and cystic fibrosis (CF).

For further information, refer to the detailed Exocrine Pancreatic Insufficiency Unmet Needs, Exocrine Pancreatic Insufficiency Market Drivers, and Exocrine Pancreatic Insufficiency Market Barriers, click here for Exocrine Pancreatic Insufficiency Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/exocrine-pancreatic-insufficiency-epi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Exocrine Pancreatic Insufficiency Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for Exocrine Pancreatic Insufficiency. The companies which have their Exocrine Pancreatic Insufficiency drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, AzurRx BioPharma, Inc., Abbott, Digestive Care, Inc. etc.

DelveInsight's Exocrine Pancreatic Insufficiency pipeline report covers around 5+ products under different phases of clinical development like
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Request a sample and discover the recent advances in Exocrine Pancreatic Insufficiency Ongoing Clinical Trial Analysis and Medications, click here @ Exocrine Pancreatic Insufficiency Treatment Landscape- https://www.delveinsight.com/sample-request/exocrine-pancreatic-insufficiency-epi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Exocrine Pancreatic Insufficiency Companies
Digestive Care, Inc., AzurRx BioPharma, Inc., Abbott, Orlando Health, Inc., Chiesi Farmaceutici, and others.

Exocrine Pancreatic Insufficiency pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Oral
• Intramuscular
• Intravenous
• Molecule Type

Exocrine Pancreatic Insufficiency Products have been categorized under various Molecule types such as
• Recombinant proteins
• Pancreatic enzymes
• Product Type

Dive deep into rich insights for drugs for Exocrine Pancreatic Insufficiency Pipeline, click here @ Exocrine Pancreatic Insufficiency Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/exocrine-pancreatic-insufficiency-epi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Exocrine Pancreatic Insufficiency Pipeline Report
• Coverage- Global
• Exocrine Pancreatic Insufficiency Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Exocrine Pancreatic Insufficiency Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Exocrine Pancreatic Insufficiency Companies- Digestive Care, Inc., AzurRx BioPharma, Inc., Abbott, Orlando Health, Inc., Chiesi Farmaceutici, and others.
• Exocrine Pancreatic Insufficiency Therapies- SA-001, EUR-1008 (APT-1008), adrulipase, and others.

Got Queries? Find out the related information on Exocrine Pancreatic Insufficiency Mergers and acquisitions, Exocrine Pancreatic Insufficiency Licensing Activities @ Exocrine Pancreatic Insufficiency Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/exocrine-pancreatic-insufficiency-epi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Exocrine Pancreatic Insufficiency: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Exocrine Pancreatic Insufficiency - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Exocrine Pancreatic Insufficiency Collaboration Deals
9. Mid Stage Products (Phase II)
10. Recombinant lipase: AzurRx BioPharma/Mayoly-Spindler
11. Drug profiles in the detailed report…..
12. Pre-clinical and Discovery Stage Products
13. Drug profiles in the detailed report…..
14. Inactive Products
15. Exocrine Pancreatic Insufficiency Key Companies
16. Exocrine Pancreatic Insufficiency Key Products
17. Exocrine Pancreatic Insufficiency- Unmet Needs
18. Exocrine Pancreatic Insufficiency- Market Drivers and Barriers
19. Exocrine Pancreatic Insufficiency- Future Perspectives and Conclusion
20. Exocrine Pancreatic Insufficiency Analyst Views
21. Exocrine Pancreatic Insufficiency Key Companies
22. Appendix

List of Important Links-

https://www.wowonder.xyz/read-blog/65223
https://diccut.com/germandennydones
https://us.newyorktimesnow.com/dennydones9193
https://www.mymeetbook.com/germanydennydones
https://wiwonder.com/1716272393254738_2674
https://www.japanesewomenorg.com/read-blog/15585
https://tannda.net/read-blog/62770
https://evahno.com/read-blog/22402
https://www.pickmemo.com/read-blog/307268
https://ai.ceo/read-blog/132421
https://www.truthsocialviet.com/read-blog/58205
https://hanzuzhisheng.com/read-blog/489
https://www.testimonyforgod.com/read-blog/3019
https://www.skillsire.com/germandennydones
https://meetplayer.com/8a48fed02
https://zekond.com/read-blog/37531
https://shareyoursocial.com/germanydennydones
https://www.snipesocial.co.uk/dennydones9911
https://social.studentb.eu/read-blog/182065

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.